Zobrazeno 51 - 60
of 145
pro vyhledávání: '"Muneer H. Abidi"'
Autor:
Pamela A Jacobson, Cheryl Cadotte, David J. Edwards, Rami B. Ibrahim, Jason Mulawa, Simon Cronin, Muneer H. Abidi, Daryn Smith, Joseph P. Uberti, Lois Ayash
Publikováno v:
Journal of Oncology Pharmacy Practice. 14:113-121
Aprepitant (AP) is a known inhibitor of cytochrome P450 3A4 which may affect tacrolimus metabolism. We retrospectively examined the effect of oral AP on intravenous tacrolimus concentrations in 26 patients undergoing reduced intensity transplantation
Publikováno v:
Transplant Infectious Disease. 10:48-51
In this report, we describe a case of Rhodococcus equi lung infection diagnosed in an allogeneic hematopoietic stem cell transplant with oral graft-versus-host disease 3 months after stem cell infusion. The lung lesion persisted despite an approximat
Autor:
E. Abella, Thomas Braun, J. L. Klein, Muneer H. Abidi, Edward Peres, S. Mellon-Reppen, Roger Dansey
Publikováno v:
Journal of Immunotherapy. 30:562-566
Metastatic renal cell carcinoma (RCC) is a disease that is resistant to conventional systemic therapy. Nonmyeloablative allogeneic stem cell transplant has activity in patients with metastatic RCC. This approach has been used in related donor transpl
Autor:
J.L. Klein, Daryn Smith, Lance K. Heilbrun, S. Narreddy, Edward Peres, Muneer H. Abidi, George Alangaden, S. Mellon-Reppen, Pranatharthi H. Chandrasekar
Publikováno v:
Transplant Infectious Disease. 9:3-10
Data on non-bacterial infections during allogeneic non-myeloablative hematopoietic stem cell transplantation (HSCT) are widely different. We evaluated data on 48 consecutive patients who received a conditioning regimen with fludarabine and cyclophosp
Autor:
William A, Wood, Jennifer, Le-Rademacher, Karen L, Syrjala, Heather, Jim, Paul B, Jacobsen, Jennifer M, Knight, Muneer H, Abidi, John R, Wingard, Navneet S, Majhail, Nancy L, Geller, J Douglas, Rizzo, Mingwei, Fei, Juan, Wu, Mary M, Horowitz, Stephanie J, Lee
Publikováno v:
Cancer. 122(1)
In hematopoietic cell transplantation (HCT), current risk adjustment strategies are based on clinical and disease-related variables. Although patient-reported outcomes (PROs) predict mortality in multiple cancers, they have been less well studied wit
Autor:
Muthu Veeraputhiran, Tania Jain, Lois Ayash, Divaya Bhutani, Voravit Ratanatharathorn, Abhinav Deol, Joseph P. Uberti, Muneer H. Abidi, Gregory Dyson, Seongho Kim, Lawrence G. Lum
Publikováno v:
Clinical lymphoma, myelomaleukemia. 15(9)
Background Salvage autologous stem cell transplantation (ASCT) is increasingly used for eligible patients with multiple myeloma (MM) for progress after conventional chemotherapy. We recently used BEAM (BCNU, etoposide, cytarabine, and melphalan) cond
Autor:
Daryn Smith, E. Abella, Edward Peres, J. Klein, Lance K. Heilbrun, Muneer H. Abidi, M M Gumma, Rami B. Ibrahim, Roger Dansey, N Milan
Publikováno v:
Bone Marrow Transplantation. 35:1071-1077
Few attempts have been made to examine the feasibility of safely administering low-molecular-weight-heparins (LMWHs) in the presence of concurrent thrombocytopenia. We retrospectively investigated the safety of low-dose LMWH in BMT patients, a popula
Autor:
Muneer H. Abidi, E. Abella, Süreyya Savaşan, D Kukuruga, J. Klein, Edward Peres, Anwar N. Mohamed, R. Lamba
Publikováno v:
Leukemia. 18:1681-1686
We retrospectively analyzed the prognostic significance of mixed chimerism and associated clinical parameters in 80 patients following unmanipulated allogenic stem cell transplantation. Chimerism studies were performed on marrow aspirates using fluor
Publikováno v:
Annals of Pharmacotherapy. 38:1053-1059
OBJECTIVE: To describe the evidence assessing the use of anti-thrombin III (AT-III) in the management of toxicity associated with hematopoietic stem-cell transplantation (HSCT)—conditioning regimens. DATA SOURCES: Clinical literature was accessed t
Publikováno v:
American Journal of Health-System Pharmacy. 68:135-137
Purpose A case of systemic lidocaine exposure in a bone marrow transplant recipient with severe hepatic sinusoidal obstruction syndrome (SOS) receiving treatment with lidocaine patch 5% is reported. Summary A 35-year-old Caucasian man with a history